Skip to main content
An official website of the United States government
The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Search:
Agenda
Reg Review
ICR
This script is used to control the display of information in this page.
Display additional information by clicking on the following:
All
Brief and OIRA conclusion
Abstract/Justification
Legal Statutes
Rulemaking
FR Notices/Comments
IC List
Burden
Misc.
Common Form Info.
Certification
View Information Collection (IC) List
View Supporting Statement and Other Documents
Please note that the OMB number and expiration date may not have been determined when this Information Collection Request and associated Information Collection forms were submitted to OMB. The approved OMB number and expiration date may be found by clicking on the Notice of Action link below.
View ICR - OIRA Conclusion
OMB Control No:
0910-0014
ICR Reference No:
201105-0910-011
Status:
Historical Active
Previous ICR Reference No:
200905-0910-005
Agency/Subagency:
HHS/FDA
Agency Tracking No:
Title:
Investigational New Drug Regulations
Type of Information Collection:
Revision of a currently approved collection
Common Form ICR:
No
Type of Review Request:
Regular
OIRA Conclusion Action:
Approved with change
Conclusion Date:
04/16/2012
Retrieve Notice of Action (NOA)
Date Received in OIRA:
05/31/2011
Terms of Clearance:
In accordance with 5 CFR 1320, the information collection is approved for three years. Following approval of this ICR, FDA will discontinue the following control numbers: 0910-0651 and 0910-0653. In the future, the agency should consider collapsing the ICs into categories (e.g., recordkeeping, reporting) and should provide meaningful titles to each IC in ROCIS to make the information provided to the public clearer. It is not appropriate to use only a provision number as a title for an IC. The agency is also reminded that failure to properly identify and explain the information contained in the ICR can be the basis for an improper submission. Regulatory citations must be correct in both the supporting statement and ROCIS and fully described in the supporting statement.
Inventory as of this Action
Requested
Previously Approved
Expiration Date
04/30/2015
36 Months From Approved
04/30/2012
Responses
2,685,772
0
2,744,640
Time Burden (Hours)
141,870,849
0
141,492,162
Cost Burden (Dollars)
0
0
0
Abstract:
Information collection from applicants who apply for approval of an investigational new drug application in order to develop a drug for marketing.
Authorizing Statute(s):
US Code:
21 USC 355(i)
Name of Law: FFDCA
Citations for New Statutory Requirements:
US Code: 21 USC 312 Name of Law: FFDCA
Associated Rulemaking Information
RIN:
Stage of Rulemaking:
Federal Register Citation:
Date:
Not associated with rulemaking
Federal Register Notices & Comments
60-day Notice:
Federal Register Citation:
Citation Date:
76 FR 4914
01/27/2011
30-day Notice:
Federal Register Citation:
Citation Date:
76 FR 27328
05/11/2011
Did the Agency receive public comments on this ICR?
No
Number of Information Collection (IC) in this ICR:
59
IC Title
Form No.
Form Name
312.10 Applications for waiver of requirements under part 312
312.110(b) Request to export and investigational drug
312.110(b) Request to export an investigational drug
312.120 Submissions related to foreign clinical studies not conducted under an IND
312.130(d) Biologics; Request for disclosable information for investigations involving an exception from informed consent
312.130(d) Request for disclosable information for investigations involving an exception from informed consent
312.160(a)(3) Biologics; Records maintenance: shipment of drugs for investigational use in laboratory research animals or in vitro tests
312.160(c) Biologics; Shipper records of alternative disposition of unused drugs
312.160(c) Shipper records of alternative disposition of unused drugs
312.2(e) Request for advice on applicability of part 312
312.23 Investigational New Drug submission
312.23 and 312.120(b)(c)(2)(c)(3). Biologics; Investigational New Drug Submission
312.30(a)-(e) Biologics; Protocol Amendments
312.30(a)-(e) Protocol Amendments
312.31(b) Biologics; Information amendments
312.31(b) Information Amendments
312.310(b) and 312.305(b) Submissions related to expanded access and treatment of an individual
312.310(d) Emergency use of an investigational new drug
312.315(c) and 312.305 (b) Submissions related to expanded access and treatment of an individual patient.
312.32(c)(d) and 312.56(c) Biologics; Safety Reports and Notifications
312.32(c)-(d) Safety Reports
312.320 Submissions related to treatment IND or treatment protocol
312.33 Annual Reports
312.33(a) -(f) and 312.56(c) Biologics; Annual reports and related notifications
312.38(b)(c) Biologics; Notification of withdrawal of an IND
312.38(b)(c) Notification of withdrawal of an IND
312.42(e) Biologics; Request to remove clinical hold
312.42(e) Request to remove clinical hold
312.44(c) and (d) Biologics; Response to termination of IND
312.44(c)(d) Response to termination of IND
312.45(a) and (b) Biologics; Request for or response to inactive status determination
312.45(a)(b) Request for or response to inactive status determination
312.47(b) Biologics; End-of-Phas 2 and Pre-NDA meetings
312.47(b) End-of-Phase 2 and Pre-NDA meetings
312.52(a) Biologics; Transfer of obligations to a contract research organization
312.52(a) Transfer of obligations to a contract research organization
312.53(c) Biologics; Investigator Information
312.53(c) Investigator Information
312.54(a) and (b) Biologics; Submissions concerning exception from informed consent under 50.24
312.54(a)(b) Submissions concerning exception from informed consent under 50.24
312.55(b) Biologics; Sponsor reports on new observations; e.g. adverse reactions and safe use
312.55(b) Sponsor reports on new observations, e.g. adverse reactions and safe use
312.56(b) and (d) Biologics; Sponsor monitoring of clinical investigations; notification to FDA
312.56(b)(c)(d) Sponsor monitoring of investigations;notifications to FDA
312.57 Sponsor recordkeeping
312.57(a)(b) Biologics; Sponsor recordkeeping
312.58(a) Biologics; Sponsor submission of records
312.58(a) Submission of records to FDA
312.60(a)(3)Records of shipment of drugs for investigational use in laboratory research animals or in vitro tests
312.62(a) Biologics; Investigator recordkeeping of disposition of drugs
312.62(a) Investigator recordkeeping of disposition of drugs
312.62(b) Biologics; Investigator recordkeeping of case histories of individuals
312.62(b) Investigator recordkeeping of case histories of individuals
312.64 Investigator reports to the sponsor
312.64 Investigator Reports to the sponsor
312.70(a) Biologics; Investigator disqualification - opportunity to respond
312.70(a) Investigator disqualification; opportunity to respond
312.8 Biologics; Charging for investigational drugs under an IND
312.8 Charging for investigational drugs under an IND
Investigational New Drug Regulations
Investigational New Drug Regulations
ICR Summary of Burden
Total Approved
Previously Approved
Change Due to New Statute
Change Due to Agency Discretion
Change Due to Adjustment in Estimate
Change Due to Potential Violation of the PRA
Annual Number of Responses
2,685,772
2,744,640
0
-41
-58,827
0
Annual Time Burden (Hours)
141,870,849
141,492,162
0
-940
379,627
0
Annual Cost Burden (Dollars)
0
0
0
0
0
0
Burden increases because of Program Change due to Agency Discretion:
No
Burden Increase Due to:
Burden decreases because of Program Change due to Agency Discretion:
No
Burden Reduction Due to:
Short Statement:
The hour changes for this ICR are the result of burden hours associated with new rulemaking that have been added to this extension. These new burden hours are indicated in the following "21 CFR sections" of Table 1: 312.2(e); 312.8; 312.10; 312.120; 312.310(b) & 312.305(b); 312.310(d); 312.315(c) & 312.305(b); and 312.320.
Annual Cost to Federal Government:
$63,679,000
Does this IC contain surveys, censuses, or employ statistical methods?
No
Is the Supporting Statement intended to be a Privacy Impact Assessment required by the E-Government Act of 2002?
No
Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]?
No
Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]?
No
Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)?
No
Is this ICR related to the Pandemic Response?
Uncollected
Agency Contact:
Eliazabeth Berbakos 3018271482
Common Form ICR:
No
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(a) It is necessary for the proper performance of agency functions;
(b) It avoids unnecessary duplication;
(c) It reduces burden on small entities;
(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;
(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;
(f) It indicates the retention periods for recordkeeping requirements;
(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.
(i) It uses effective and efficient statistical survey methodology (if applicable); and
(j) It makes appropriate use of information technology.
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
Certification Date:
05/31/2011